Member Info for SmartVestor

Neat work Tbird :-) something in this IMVHO Are PIRI about to enter the Lithium Business ? it looks very possible now

Thunderbird,now that is an interesting development !! if this becomes a lithium play shortly i think there will be alot folks wanting a piece of it.

I would not be suprised to see that happen,the two new guys at PIRI that were appointed a while ago would also fit in that scenario as they have experience in that area.Could be some very interesting times ahead here and it may even mirror what happened at REM.

Well PIRI have been obviously quietly working away on something,if it is the European Lithium IPO you will see some truly amazing gains here in my opinion.I researched that the other day and it looks a very solid play indeed and will only grow with Lithium demand as it is and forecast to grow.Worth tucking these away !

There are rumours that PIRI will be involved with this float,if so you may see a quick 5 bagger here guys

Makes you wonder if the BoD have something up their sleeve ? they seem to have done nothing so far to avoid max slipping into this position.So yes a toss of a coin is a fair description of where this could end up. Keeping an eye on ALR at moment too,signs that some major news is in the offing.

Just been reading up on John May,he is a very well connected guy indeed,

Just found this on the other side,it would appear that some major news is brewing! 22 Jan'15 - 12:36 - 2903 of 2903 Guys a very interesting development this morning,piri recent board appt Mr John May has just been appointed to the board of European Lithium and also on to their audit committee.Reason this is of interest is their was a rumour around last week that Piri are going to invest in their upcoming IPO. Is this a coincidence ?

Millwall,check out this recent post over at the interactive bb,i wonder if this IPO is what PIRI have been keeping their powder dry for ? it certainly does look an interesting possible move ! 12:21 - 10/01/2015 - Re: 2015 i have been keeping an eye on this company in the last few months and think it could be one of those dark horse plays that pulls a few nice suprises out the hat.At the moment they have a market cap of just £900k which looks far too cheap considering thay have £600k of cash and other investments valued around £1m.Also no debt and a clean balance sheet. I have a few pals in the city that follow smallcaps and the word is that PIRI are likely to be involved with the upcoming IPO of European Lithium Ltd,which from some initial research i have done does look like it could be one of the most exciting stockmarket floats of recent years.Recent appointments here of John May and Mr Gonzales could be to oversee that investment ( judging by their history ).It would be a very smart move if Piri do take an initial stake there as it is one of those type of investments that could multiply in value very quickly,and early investees and warrant holders could see some exceptional returns. I found these recent press articles on European Lithium Ltd which are worth a read. http://tinyurl.com/musq5nx

Millwall,i was watching this for last two hours today on level 2 today and i think there were a couple of huge whacking buys they have not published yet.I was not able to get a buy quote at all for nearly an hour and then just before close all the MM,s moved to a 0.05p ask.So it does appear there were some biggie buys they have hidden while they moved the spread out. To me that is a sign that some potentially juicy news is imminent here !

This looks a cracking buy to me,i would not be suprised if they offered some very big dividends to shareholders soon and maybe even a whacking special divi !

Order was set just incase some cheapies go on offer,it could turn into a decent recovery situation though so worth keeping an eye on.

I think this is being heavily shorted at moment and they could tank it right down during next few days,i have set a buy order at 3.275p,possible that an existing major shareholder is doing it and could be balancing their position.It looks like they have shaken loads of folks out last few days while the "re-structure" is worked out.

In the latest update to our GOLDEN FIVE shares for 2013,the future for specialist engineering company MDM Group ( LON:MDM ) is looking very bright.The company has come up with some impressive year end earnings figures and announced a 263% increase in its final dividend.Forecasts suggest that the group is ontrack to deliver further impressive growth over the next 3 years and maintain a progressive dividend yield of at least 9% rising to as high as 14% by 2015.The company revealed its order book is bulging and have a strong pipeline of future projects on the table.There has also been sustained rumours that a Singapore based Equity Group has been eyeing the group for a takeover,with figures of £2.25 - £2.65 per share muted.MDM reported a massive jump in pre-tax earnings of 161% - from to US$ 7.8 million in 2011 to $29.1 million in its 2012/13 financial year which ended March 31st. After tax earnings came to US$ 14.2 million (2012: US$ 5.8 million) resulting in basic earnings per share of US 37.78 cents per share (2011: US 15.37 cents) . This has enabled it to increase its final dividend by an even larger percentage, from US 5.2 cents to US18.9 cents,although this year’s final payout includes a US 6 cent special dividend in the light of the company’s big increase in its year-end cash balance from US$29.1 million to US$34.6 million.The company is committed to pay 50% of after-tax profits as a dividend to shareholders.We consider the shares will undergo a dramatic re-rating shortly as the great story here gets out,and the income seekers discover what should be a solid 10% returner,plus significant growth in the shareprice over the next few years. There is still time to get this years bumper payout and the special dividend as it goes ex-dividend on the 10th July.We maintain our "Strong Buy and Hold" rating on the stock.

This weeks dividend of the week reported last week and declared a 15.6% increase in their dividend whilst at the same time promising a further 15% dividend increase in the next financial year. That is a pretty good start if you want to be dividend of the week. So, the dividend of 6.95p is in the bag and goes ex-dividend on 3rd July. After that, the forecasts are for 3.95p at the interim stage and another 8p at the finals stage about a year from now, so you can expect to pick up around about 19 pence per share between now and July 2014 for an annualised yield approaching 7% (6.85% at yesterdays close).Unfortunately, they are not cheap as they have been justifiably re-rated over the past 12 months on the back of a very strong business performance. The recent numbers were affected by some one-offs and underlying earnings per share actually grew at just shy of 21%. The one off was incurred via a £62 million investment in their TV business, which they now boast is the UK’s fastest growing TV business, which you would expect quite shortly after launch. Analysts are expecting pre-tax profits to grow to roughly £194m next year and £250m the following year from £122m in the year just gone. They have a couple of exciting years ahead of them and seem to have a fully focused business. There are rich pickings to be had in this huge industry and the more nimble players such as TalkTalk should do very well on a 3-5 year view. It is obviously underpinned by a pretty good dividend and the promise of more to come, at least for next year. I would expect the growth story to continue beyond that. Our dividend of the week is TalkTalk.

Broker Round-up part 2: May 13 2013, 3:20pm City broker Panmure Gordon has hailed the cash balance of Tissue Regenix (LON:TRX), whose patented technology allows human or animal tissue to be used again for skin or body part replacement in other patients. Looking back over the year just gone, the company said it has made significant progress towards commercialising its regenerative medical technology. Panmure said that at £24.2mln the cash balance was slightly higher than forecast and while the addition of US infrastructure will accelerate cash burn, it demonstrates that Tissue Regenix remains on a good trajectory for growth. The company has also received good data on its dermis product, while there is growing evidence of stem cells being attracted to re-populate the company’s dCELL matrix in vascular patches, said the broker. The marquee product, its heart valve technology that is already on the market in Brazil, now also has eight years’ worth of supporting data.Panmure believes that if become Tissue’s technology platform becomes successfully commercialised it will become a bid target.“It has multiple shots at goal and a strong balance sheet to execute its strategy. Therefore, we remain buyers and re-iterate our price target of 18p,” said the broker. http://tinyurl.com/d7662tx

Briefly they have just had a significant approval from the Nhs and will be adopted in the Nhs this summer,so with a large part of their tech now proven it is a possible that one of the big medical companies could take an early option on this and sign some deals.When you have a truly unique technology like this that can save healthcare providers huge sums in their budgets the commercial appeal is obvious.Watch this space as they could announce something anytime,they were in the states last week and now within a few days they have said this "“We are also moving ahead with our expansion into the US, and are currently in discussions with prospective product manufacturers and distributors, as well as exploring the possibility of clinical trials with major academic institutions"". Upside here could be spectacular IMO

Tissue Regenix (LON:TRX) had made significant progress towards commercialisation of its regenerative medical technology over the past year.The company, which has a patented technology, dCELL, that allows human or animal tissue to be used again for skin or body part replacement in other patients, added that the market for tissue engineering is large and growing quickly.In the area of wound repair and following on from a successful chronic ulcer trial in the UK, discussions have begun on initiating a clinical study in the US. Approval was also received in April for a UK clinical research trial of dCELL dermis matrix in treating acute wounds.In cardiac, a porcine pulmonary valve is being translated from the work done at the University of Leeds, and pre-clinical work is planned for this half-year.In the vascular area, a pilot study for the AV graft is now in progress and is on course for a pre-clinical study in the second half of this year.In orthopaedics, regulatory application to start a clinical trial in Europe for its knee cartilage replacement will be submitted in the first half of 2014 when biomechanical testing and refinement of the suturing technique has been completed.The ligament repair product will be in pre-clinical studies by the end of 2013 with discussions underway with the US Food and Drug Administration in respect of approval requirements for the US market. Antony Odell, Tissue Regenix’s managing director, added: “We are also moving ahead with our expansion into the US, and are currently in discussions with prospective product manufacturers and distributors, as well as exploring the possibility of clinical trials with major academic institutions and key opinion leaders to support marketing efforts in the US in 2014.“Tissue Regenix has a portfolio of dCELL Scaffolds, enabling clinicians to get the right tissue for the application area rather than trying to make one tissue type perform a multiplicity of clinical roles that it was not designed to do. As we roll out this portfolio, this clear distinction from other approaches will become an important factor in our future success.”The group posted a loss of £3.5mln (£2.7mln) in the year to January, with a closing year end cash position of £24.2mln. http://tinyurl.com/d832u7w

$21bn market targeted as TRX receives trial approval 30 Apr 2013 York-based Tissue Regenix (TRX), the regenerative medical device company, has announced that approval has been given for a clinical research trial of its dCELL dermis matrix, which will examine its effectiveness in treating acute wounds, in addition to chronic wounds which was previously evaluated in a clinical study.This trial marks an important milestone in Tissue Regenix’s plans to target the global market for chronic and acute wound care, which research firm Kalorama estimates could be worth around $21 billion by 2015. Finding more effective ways to treat acute wounds, including surgical incisions and traumatic injuries such as lacerations, abrasions, avulsions, penetrations, bites or burn injuries, would save the NHS significant sums of money, improve patient recovery times and promote more successful healing.The clinical study will be conducted by University Hospital of South Manchester NHS Foundation Trust and will involve a series of six-week trials on 50 healthy human patients, to investigate the responsiveness of acute wounds to Tissue Regenix’s dCELL dermis matrix and to clarify if dCELL dermis improves the closure of acute wounds compared to “normal” wound healing and other options.Tissue Regenix’s dCELL dermis works by taking human donor skin and removing the DNA and cells, using the patented dCELL process to leave a dermis matrix that can be placed over the wound to aid natural healing by attracting the patient’s own cells to the wound area. Antony Odell, managing director of Tissue Regenix Group plc, commented: “We are delighted that this clinical trial can now proceed.“Finding more effective ways to treat acute wounds could significantly improve the efficacy and speed of patient recovery times and save the NHS and other healthcare providers’ significant sums of money.“This builds on the work we have already been undertaking in collaboration with Dr Bayat and his team in Manchester on chronic wounds, with a clinical study which investigated successfully the efficacy of Tissue Regenix dCELL dermis matrix in healing chronic wounds such as venous ulcers.” http://bdaily.co.uk/entrepreneurship/30-04-2013/21bn-market-targeted-as-trx-receives-trial-approval/

I see your one,mine yesterday was not published at all and still not appeared today yet and it was for 122k